ASA Engage – December 2026

Details

Venue: Online only

Date: Thursday, 3 December 2026

Time: 10:00am to 2:00pm AEDT

Pricing:

Free for Members
Free for Non-Members

Register Now

About ASA Engage 2026

Join us for ASA Engage featuring senior executives from leading ASX-listed companies.

As the year draws to a close, ASA Engage gives investors a timely opportunity to hear directly from the people running the companies they own or are considering. Join us for a series of concise, high-value sessions with senior executives as they share updates on performance, strategy and outlook, and the opportunities and challenges ahead for 2027.

Each 25-minute session includes a company presentation followed by live Q&A, giving you the chance to hear first-hand from company leadership and ask your questions in real time.

Program

Time	Program Overview
10:00 – 10:25 AM	First Session – Angus Bean, DroneShield+ Expand Details Host: Rachel Waterhouse About Angus Bean, DroneShield Angus Bean is the Chief Executive Officer at DroneShield (ASX:DRO). Since joining in 2016, he has scaled the company’s Technology team to over 250 engineers and specialists, delivering globally deployed counter-uncrewed systems (C-UxS). He leads DroneShield’s Technology and AI strategy, driving the integration of mechanical systems, electronics, software, and digital interfaces into mission-focused solutions. Recognised as a finalist for Defence Connect’s Defence Executive of the Year (2024) and Defence Engineer of the Year (2019), Angus is a technology leader shaping the future of AI-driven defence innovation worldwide.
10:25 – 10:50 AM	Second Session – Cheryl Maley, Starpharma+ Expand Details Host: Rachel Waterhouse About Cheryl Maley, Chief Executive Officer, Managing Director, Starpharma Holdings Limited Cheryl Maley has over 25 years of experience in the pharmaceutical industry, including 20 years in leadership roles at well-known and leading organisations, including Novartis and AbbVie. Her previous roles include nine years at Novartis in senior commercial and executive roles and various sales and marketing positions with AbbVie/Abbott, Servier Laboratories, and Wyeth Pharmaceuticals. She has experience leading pharmaceutical innovation, marketing strategies, and business growth across Australia, Asia, and international markets. During her nine-year career at Novartis, she held senior leadership positions, responsible for new products, commercialisation, strategy, and reimbursement matters. She also held General Management roles in both the Philippines and Australia. Prior to joining Starpharma, she was Acting CEO and Strategic Advisor at Biointelect, a firm specialising in strategic planning and commercialisation for the biopharmaceutical and medical device sector. She holds a board position at Neuroscience Research Australia.
10:50 – 11:00 AM	Break
11:00 – 11:25 AM	Third Session – Craig Keary, Raiz Invest+ Expand Details Host: Rachel Waterhouse About Craig Keary, CEO, Raiz Invest Craig Keary is the chief executive officer of Raiz Investor Hub. He holds a Masters of Commerce – Financial Planning from the University of Western Sydney and a Post-Graduate Diploma of Management from Macquarie University. Craig also holds an SMSF Accreditation Certificate and a Diploma of Financial Services. He is a graduate of the Australian Institute of Company Directors.
11:25 – 11:50 AM	Fourth Session – Brett Morgan, MyState Limited+ Expand Details Host: Rachel Waterhouse About Brett Morgan, Managing Director & CEO, MyState Limited Brett commenced with the MyState Group on 17 January 2022. He was previously Chief Executive Officer, Banking and Wholesale at ASX listed BNK Banking Corporation Limited (ASX:BBC) and has extensive fintech and digital banking experience having held a number of key executive roles over 15 years at ING DIRECT.
11:50 AM – 12:00 PM	Break
12:00 – 12:25 PM	Fifth Session – Richard Seville, Advanced Engineered Materials (AEM)+ Expand Details Host: Natalie Kulakoff About Richard Seville, Executive Chairman, Advanced Engineered Materials (AEM) Company Director, former Managing Director/CEO, and Entrepreneur with over 35 years’ experience and with strong track record in mining and chemicals industry. Demonstrated performance in creating both returns for shareholders and value for other stakeholders.
12:25 – 12:50 PM	Sixth Session – Daniel Tillett, Racura Oncology+ Expand Details Host: Natalie Kulakoff About Daniel Tillett, Managing Director and Chief Executive Officer, Racura Oncology Dr Daniel Tillett is the Managing Director and Chief Executive Officer of Racura Oncology. He is a veteran executive in the biotech industry with more than 25 years of management experience and leadership in all aspects of commercial operations including strategy, IP management, sales and marketing, project management, licensing and fundraising. Dr Tillett is also the founder and CEO of Nucleics, a private Australian biotechnology company producing and selling world-leading DNA sequencing software to the genomics industry. Nucleics SAAS (software as a service) genomics tools are used in more than 30 countries and at over 250 companies and research institutions. Previously, he was a Senior Lecturer within the School of Pharmacy at La Trobe University where he taught and researched in the areas of pharmacy, phage therapy, virology, microbiology, bioinformatics and cancer. Dr Tillett has a BSc (Hons 1) and PhD from the University of New South Wales in Molecular Genetics and Biochemistry. He has more than 40 scientific publications and granted patents in molecular biology, virology, microbiology, genetics and biochemistry.
12:50 – 1:00 PM	Break
1:00 – 1:25 PM	Seventh Session+ Expand Details Host: Natalie Kulakoff
1:25 – 1:50 PM	Eighth Session+ Expand Details Host: Natalie Kulakoff
1:50 PM	Close